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Abstract
Background: Patients newly colonised with methicillin-resistant Staphylococcus aureus (MRSA) are at higher risk of
clinical MRSA infection. At present, there are limited data on the duration or magnitude of this risk in a hospital
population with a known time of MRSA acquisition.
Methods: A retrospective cohort study of 909 adult patients known to have newly identified MRSA colonisation
during admission to National University Hospital, Singapore between 1 July 2007 and 30 June 2011 was
undertaken. Patients were excluded if they had history of previous MRSA colonisation or infection, or if they had
been a hospital inpatient in the preceding 12 months. Data were collected on the development of MRSA infection
requiring hospitalisation up to 30 June 2012.
Results: Of 840 patients newly colonised with MRSA as identified on active surveillance and not clinical specimens,
546 were men (65.0%) and the median age was 65 years (range 18–103 years). Median follow up was 24 months
(range 0 –64 months, 85.1% followed >6 months). Clinical infection occurred in 121 patients (14.4%) with median
time to infection of 22 days (95% CI 14–31). Overall 71.9% (87/121) of infected patients developed infection within
60 days of the date MRSA colonisation was detected. However, 17/121 patients (14.0%) developed clinical infection
more than six months after documented MRSA acquisition. The most common sites of clinical infection were skin
and soft tissue (49/121, 40.5%, 95% CI 31.7-49.8), respiratory tract (37/121, 30.6%, 95% CI 22.5-39.6) and bone and
joint infections (14/121, 11.6%, 95% CI 6.5-18.7). Thirteen patients (13/121, 10.7%, 95% CI 5.8-17.7) had bacteraemias,
of which six (5.0% 95% CI 1.8-10.5) were primary and seven (5.7%, 95% CI 2.3-11.6) were secondary to infection at
other sites. Crude mortality at 30 days and six months was higher in patients with MRSA infection than colonisation
alone (aOR 5.49, 95% CI 2.75-10.95, p<0.001 and aOR 2.94, 95% CI 1.78-4.85, p<0.001 respectively).
Conclusion: Risk of clinical infection is highest soon after MRSA acquisition. Prevention of MRSA acquisition in
hospital will have significant impact on morbidity and mortality for patients.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) has be-
come a major cause of hospital-associated infection since
emerging in the 1960s. According to National Healthcare
Safety Network data, in 2009–2010 MRSA accounted for
8.5% of all hospital-associated infections in the United
States and was the most frequent multiresistant organism
causing hospital-associated infection [1].
MRSA infection has been associated with many nega-
tive outcomes including higher hospital costs, longer
hospital stays and higher mortality [2,3]. This has been
shown with a variety of infection sites and a range of
hospital contexts, including our own. In Singapore, pa-
tients with MRSA infection during admission were 10.2
times more likely to die during hospitalisation, had 4.6
times longer hospital stays and had hospitalisation costs
4.0 times higher than matched uninfected controls [4].
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Infections with MRSA following initial colonisation are
known to be due to the same strain in most patients [5].
Colonisation with MRSA is a major risk factor for subse-
quent MRSA infection [6-8]. This is well-established for
infection occurring in the same admission as MRSA de-
tection, and there is mounting evidence that the risk of
MRSA infection may persist for longer periods in some
colonised patients [9-13].
However, most studies have evaluated patients who
have MRSA without separately analysing incident and
prevalent MRSA carriers. Furthermore, few studies have
followed patients for more than eighteen months. To
date there are limited data on the impact of newly ac-
quired MRSA in a tertiary hospital setting. We sought to
investigate the risk of progression to infection over a five
year period in a cohort of patients who acquired MRSA
during an admission at our hospital.
Methods
Setting
National University Hospital (NUH) is a 1000 bed ter-
tiary hospital in Singapore. An MRSA control bundle
which included active surveillance cultures (ASC) at ad-
mission and discharge was introduced in Intensive Care
Units (ICUs) in 2007. The bundle was progressively ex-
panded throughout the hospital over subsequent years
such that by 2011, universal ASC on ward admission
and discharge were routine on all adult inpatient wards
except psychiatry and obstetrics. Patients transferring
between wards underwent ASC upon transfer (e.g. from
ICU to general ward). Patients colonised with MRSA
were not routinely decolonised during this study.
Design
We conducted a retrospective cohort study to evaluate
the risk of progression to infection in adult patients who
had newly acquired MRSA during an inpatient admis-
sion to NUH between 1 July 2007 and 30 June 2011.
Patients were included if they had negative ASC on ad-
mission but subsequent positive ASC during the same
admission. Patients were excluded if they had been ad-
mitted to any healthcare facility within the preceding 12
months or if they had a history of previous MRSA col-
onisation or infection. Analysis was not performed on
patients that developed MRSA infection during their
index admission if the clinical isolate grew MRSA prior
to the screen swab. That is, patients who appeared to
develop infection without evidence of prior colonisation
were not included. Only Singapore citizens or perman-
ent residents were included in the study to avoid likely
loss to follow up. Patient records were reviewed until
death or 30 June 2012 to determine if clinical MRSA in-
fection developed. In this way, we aimed to investigate
the risk of progression to infection in a group of patients
in whom we could reasonably attribute MRSA acquisi-
tion to a specific admission at our hospital.
ASC were taken using one swab from both nares, and
one from both axillae and groin on admission. Swabs were
processed as a pooled sample and inoculated on chromo-
genic media (MRSA Select, Bio-Rad Laboratories, Marnes-
la-Coquette, France) with aerobic incubation for up to 48
hours. Clinical specimens were taken at the discretion of
the primary team according to routine care and processed
using existing laboratory protocols based on the type of
sample. Prior to 2010, MRSA identification was confirmed
using Vitek2 instrument (bioMérieux, Marcy L’Etoile,
France), and from 2010 onwards, by matrix assisted
laser desorption ionisation-time of flight (MALDI-TOF,
Bruker Daltoniks GmbH, Bremen, Germany).
Data were collected retrospectively on demographics
(age, gender, ethnicity) and pre-existing co-morbidities
(diabetes, active malignancy, non-cancer immunosuppres-
sion, chronic haemodialysis). Data on healthcare utilisa-
tion during the admission in which MRSA was acquired
were also collected. This was limited to information stored
electronically but included ICU admission, surgery within
30 days of MRSA acquisition, and intravascular catheter
placement. Co-morbidities were classified using Inter-
national Classification of Diseases, Ninth Revision codes
from discharge summary records. Patients developing
MRSA clinical infection were further evaluated as to the
primary site of the infection according to NHSN defini-
tions [14], need for admission and number of days be-
tween first positive MRSA ASC and first positive culture
from a clinical site (i.e. not a surveillance culture). Out-
come data on re-admission due to MRSA infection at any
public hospital in Singapore and for mortality at one and
six months were reviewed.
The study was approved by the Domain Specific Re-
view Board for the National Healthcare Group institu-
tions in Singapore (NHG DSRB 2012/00513).
Statistical analysis
Bivariate analysis was first performed to identify variables
that showed significance at the 0.20 level with a binary out-
come, with the exceptions of age, gender and ethnicity
which were forced into the model to address the possibility
of residual confounding. To verify an association between
categorical variables, the χ-square test was employed.
Akaike and Bayesian Information Criterion (AIC/BIC) were
used as primary drivers for model building, and the model
fit was checked with the Hosmer-Lemeshow goodness-of-
fit test (by deciles). Additionally, receiver-operating curve
(ROC) plots and sensitivity/specificity tables were utilised
to assess the practical utility of the individual logistic
models. Kaplan-Meier analysis was performed to identify
the unadjusted time-to-event with associated confidence
intervals within the entire cohort. Data analysis was
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performed using Stata 12.1 (College Station, Texas); all
tests were two-tailed.
Results
From 1 July 2007 to 30 June 2011, 228968 patients were
admitted to NUH. Their average length of stay was 5.6
days. During this time, we identified 909 patients on
routine screening who were entry ASC negative but ac-
quired MRSA colonisation during their hospitalisation.
Of these, 69 patients also had MRSA isolated from clin-
ical sites before being identified as MRSA colonised
through ASC; these patients were not further analysed
(Figure 1). Of the remaining 840 patients, 546 (65.0%)
were men and the median age was 65 years (range 18–
103 years). Ethnic representation approximated the
national distribution with 68% Chinese, 18% Malay, 9%
Indian and 5% other (Table 1). The median time be-
tween admission (negative ASC) and known colonisation
(first detected positive ASC) was 11 days. Patient records
were reviewed until death or 30 June 2012; the median
duration of this review was 24 months and 85.1% (715/
840) were followed for >6 months.
Clinical MRSA infection developed in 121 of 840 pa-
tients (14.4%) within the follow up period. The median
time to infection was 22 days from the time of positive
ASC (95% CI 14–31). The majority of patients develop-
ing clinical infection did so soon after acquisition, with
42.1% (51/121, 95% CI 33.2-51.5) presenting with infec-
tion within 14 days of MRSA acquisition (Figure 2). This
increased to 57.8% (70/121, 95% CI 49.4-67.6) by 30 days
and 71.9% (87/121, 95% CI 63.0-79.7) at two months.
Eighty-two patients (82/121, 67.8%, 95% CI 58.7-76.0)
developed MRSA infection after discharge and had the
infection detected at an outpatient clinic visit or at a
subsequent admission. This included a minority of pa-
tients with onset of infection more than six months after
documented MRSA acquisition (17/121, 14.0%, 95% CI
8.4-21.5). Alternatively from a patient perspective: if
MRSA infection had not occurred within 60 days of
colonisation then we observed the future risk of MRSA
infection to be just 4% (34/840, 95% CI 2.8-5.6).
The most common sites of clinical infection were skin
and soft tissue (49/121, 40.5%, 95% CI 31.7-49.8), re-
spiratory tract (37/121, 30.6%, 95% 22.5-39.6) and bone
and joint infections (14/121, 11.6%, 95% CI 6.5-18.7).
Thirteen patients (13/121, 10.7%, 95% CI 5.8-17.7) had
bacteraemias, of which six (5.0% 95% CI 1.8-10.5) were
primary and seven (5.7%, 95% CI 2.3-11.6) were second-
ary to infection at other sites.
Surgery within 30 days (OR 1.50, 95% CI 1.01-2.21,
p=0.043) as well as admission to ICU during the index
admission (OR 1.50, 95% CI 1.02 – 2.22, p=0.039) were
associated with MRSA infection (Table 2). Patients who
were immunosuppressed (non-malignancy related im-
munosuppression) appeared to have a lower risk of de-
veloping infection if colonised (OR 0.11, CI 0.028-0.478,
p=0.002). No demographic or medical exposures apart
from age were associated with development of clinical
infection on multivariate logistic regression analysis.
Clinical infection seemed more likely to develop in
those aged 60–79 years, and was more common in
males although these trends did not reach statistical sig-
nificance. In this cohort of patients with known time of
MRSA acquisition, we did not identify any comorbid
Figure 1 Study design. Study design and distribution of study population.
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conditions or exposures during their admission that
were associated with increased risk of developing subse-
quent MRSA infection. However, MRSA infection was
strongly associated with mortality (Table 3). Of the 840
patients studied, 125 died within six months of MRSA
acquisition. In patients developing MRSA infection after
being colonised, 16.5% (20/121) died either during ad-
mission or within 30 days of discharge from the admis-
sion in which they acquired MRSA. An additional 15
patients who developed MRSA infection (15/121, 12.4%,
95% CI 10.4-24.4) died within six months of MRSA ac-
quisition. MRSA infection increased the risk of death at
30 days over fivefold compared to patients who were
only colonised (aOR 5.49, 95% CI 2.75-10.95, p<0.001).
Risk of death remained elevated at six months (aOR
2.94, 95% CI 1.78-4.85, p<0.001). Of patients surviving
to discharge, those who developed MRSA infection were
less likely to be discharged to their own home (p=0.04)
and 32/121 patients (26.4%) required multiple admis-
sions for complications of MRSA infections.
Table 1 Demographic and clinical characteristics of colonised (n=716) and infected patients (n=121)
Colonised patients (%) Infected patients (%) Total (%)
Age (years)
≤ 39 83 (11.5%) 7 (5.8%) 90 (10.7%)
40-59 209 (29.1%) 30 (24.8%) 239 (28.5%)
60-79 298 (41.4%) 65 (53.7%) 363 (43.2%)
80 + 129 (17.9%) 19 (15.7%) 148 (17.6%)
Gender
Male 460 (64.0%) 86 (71.1%) 546 (65.0%)
Female 259 (36.0%) 35 (28.9%) 294 (35.0%)
Ethnicity
Chinese 485 (67.5%) 85 (70.2%) 570 (67.9%)
Malay 131 (18.2%) 20 (16.5%) 151 (18.0%)
Indian 65 (9.0%) 11 (9.1%) 76 (9.0%)
Other 38 (5.3%) 5 (4.1%) 43 (5.1%)
Co-morbidities
Diabetes 233 (32.4%) 45 (37.2%) 278 (33.1%)
Active malignancy 66 (9.2%) 18 (14.9%) 84 (10.0%)
Haemodialysis 246 (34.2%) 49 (40.5%) 295 (35.1%)
Non-cancer immunosuppression 91 (12.7%) 2 (1.7%) 93 (11.1%)
Exposures
Surgery within 30 days 350 (48.7%) 71 (58.7%) 421 (50.1%)
ICU admission 325 (45.2%) 67 (55.4%) 392 (46.7%)
Central line placement 237 (33.0%) 50 (41.3%) 287 (34.2%)
Outcome
Mortality at 30 days 33 (4.6%) 20 (16.5%) 53 (6.3%)
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Figure 2 Kaplan-Meier estimates of clinical MRSA infection
from time of colonization (months) (n=840). Kaplan-Meier
estimate showing proportion of patients with clinical MRSA infection
shown at six-monthly time intervals.
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Table 2 Risk factors for clinical infection (n=840) (Outcome defined as MRSA-positive clinical infection)
Crude odds ratio (95% C.I.) Adjusted odds ratio (95% C.I.) p value
Age (years)
≤ 39 1.0 (ref) 1.0 (ref) -
40-59 1.70 (0.72 – 4.03) 1.85 (0.78 – 4.40) 0.163
60-79 2.59 (1.14 - 5.85) 2.90 (1.27 – 6.61) 0.012
80 + 1.75 (0.70 – 4.33) 2.15 (0.85 – 5.45) 0.106
Gender
Male 1.0 (ref) 1.0 (ref) -
Female 0.73 (0.47 – 1.10) 0.67 (0.43 – 1.03) 0.066
Ethnicity
Chinese 1.0 (ref) 1.0 (ref) -
Malay 0.87 (0.52 - 1.47) 0.93 (0.54 -1.60) 0.799
Indian 0.97 (0.49 - 1.90) 1.01 (0.51 – 2.04) 0.959
Other 0.75 (0.29 - 1.96) 0.86 (0.32 - 2.31) 0.772
Co-morbidities
Immunosuppression 0.11 (0.03 - 0.48) 0.11 (0.03 - 0.44) 0.002
Bolded entries are significant at p < 0.05.
Table 3 Risk factors for mortality (n=840) (Outcome defined as all-cause mortality)
Mortality at 30 days Mortality at six months
Adjusted odds ratio (95% C.I.) p value Adjusted odds ratio (95% C.I.) p value
Infection group
Clinical MRSA 5.49 (2.75- 10.95) < 0.001 2.94 (1.78 – 4.85) < 0.001
Age (years)
≤ 39 1.0 (ref) - 1.0 (ref) -
40-59 0.61 (0.11 – 3.52) 0.584 2.28 (0.50 – 10.34) 0.285
60-79 1.91 (0.40 – 9.06) 0.417 5.17 (1.21 – 22.02) 0.026
80 + 2.53 (0.50 – 12.74) 0.260 16.45 (3.78 – 71.50) < 0.001
Gender
Male 1.0 (ref) - 1.0 (ref) -
Female 1.92 (1.03 – 3.60) 0.040 0.98 (0.63 – 1.51) 0.919
Ethnicity
Chinese 1.0 (ref) - 1.0 (ref) -
Malay 0.39 (0.13 – 1.18) 0.096 0.55 (0.27 – 1.11) 0.096
Indian 1.03 (0.32 – 3.30) 0.964 0.97 (0.46 to 2.08) 0.936
Other 0.46 (0.05 – 4.04) 0.479 0.42 (0.09 – 1.85) 0.251
Co-morbidities
Malignancy 2.29 (1.05 – 5.03) 0.038 2.32 (1.33 – 4.04) 0.003
Immunosuppression 2.98 (1.30 – 6.80) 0.010 NS NS
Inpatient risk factors
Surgery ≤ 30 days 0.35 (0.17 – 0.69) 0.003 0.56 (0.35 -0.90) 0.016
ICU 2.50 (0.98 - 6.39) 0.055 NS NS
CVC 3.82 (1.60 – 9.12) 0.003 2.40 (1.51 – 3.83) < 0.001
Bolded entries are significant at p < 0.05.
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Discussion
This study shows that the highest risk for MRSA infection
occurs shortly after patients become colonised. However,
a significant proportion of these patients will present with
their infection in a different admission to that in which
they became colonised. Furthermore, there is a strong as-
sociation between developing MRSA infection and death
within six months. Our study is novel in that it evaluates a
large cohort of patients with an identified likely time of
MRSA acquisition. In this group, 14.4% progressed to in-
fection with MRSA. Other studies, most of which did not
distinguish between incident and prevalent carriers, have
estimated this risk between 8.5% and 33% [6,7,10-13]. The
risk of infection was much higher in the period around
the time of the index admission shortly after the initial ac-
quisition. Over 40% of those developing clinical infections
did so within two weeks of first evidence of MRSA acqui-
sition, and 72% presented within 60 days of first evidence
of MRSA acquisition. Risk of infection appears highest in
the first few months following MRSA acquisition. This
situation may be similar to colonisation by S. pneumoniae
and N. meningitidis where an interplay between host im-
munological factors and bacterial factors results in in-
vasive disease occurring shortly after colonisation with a
new bacterial strain, while some individuals remain co-
lonised for years without infection [15,16]. In addition,
healthcare associated risk factors such as the use of de-
vices resulting in breach of normal host defences are likely
to contribute to the development of infection. In our co-
hort recent surgery, ICU admission and central line place-
ment were all associated with higher infection rates on
bivariate analysis; however, these were not significant inde-
pendent risk factors on multivariate analysis possibly due
to the relatively small number of actual infections docu-
mented. Similar associations with MRSA infection have
been found in other studies [7,12,17].
MRSA infections represent a considerable burden on
the health care system. In our study, 67.8% (82/121) of in-
fections presented in different admissions to the index ad-
mission in which the acquisition occurred, and 26.4% (32/
121) of patients required multiple admissions for features
or complications of MRSA infection. Other studies have
recently highlighted the ongoing risk of infection following
detection of MRSA colonisation [12,13]. In a large retro-
spective cohort of patients with newly detected MRSA col-
onisation or infection in the United States, 33% developed
infections over the subsequent year and the majority of in-
fections occurred after patients were discharged from hos-
pital [13]. This is an important consideration with the
tendency for shorter hospital stays as it places more
reliance on post-discharge surveillance with adequate out-
patient follow up of patients to detect and manage poten-
tial complications. Furthermore, 30 day all-cause mortality
was over fivefold higher in MRSA colonised patients
who developed clinical infections compared with those
who did not, with significantly elevated risk of mortality
persisting at six months also. Other studies have found
a similar association between MRSA infection and mor-
tality [10,13].
Prevention of MRSA acquisition is probably important
in reducing subsequent development of MRSA infection
and associated morbidity and mortality. Screening of pa-
tients to identify inpatient acquisition of MRSA colon-
isation is important in many settings, particularly if it is
linked to infection prevention interventions that may re-
duce subsequent MRSA infection in these individuals.
Surveillance programmes may be expensive in terms of
resource use and financial costs, but can be cost effective
in the long term [4,18,19]. Decolonisation of newly iden-
tified carriers, particularly in higher risk groups such as
those with invasive devices or admitted to ICU, may be
a useful addition to present standard strategies [19,20].
Strengths of this study include the large cohort of pa-
tients identified as acquiring MRSA during admission to
a tertiary hospital. Excluding patients with any past his-
tory of MRSA and indeed any admission in the preced-
ing 12 months strengthens the likelihood that the
identification of acquisition was accurate. Patients were
followed for up to five years (median 24 months),
allowing evaluation of the longer-term risks of MRSA
acquisition.
This is a single centre, retrospective study using elec-
tronic data collection methods. Frequency of ACS was
limited to that performed routinely according to hospital
policy. This poses some limitations on the study. We in-
cluded patients who were likely to remain in the study re-
gion for the follow up period and captured data by search
of shared electronic records regarding encounters at any
public healthcare facility in Singapore, but we cannot
search for admission to private hospitals or visits to com-
munity doctors. However, the referral patterns in Singapore
with its small number of hospitals means that the number
lost would not be large. We were also only able to capture
data that was systematically collected on the electronic
record. This limited some information regarding expo-
sures including prior antibiotic use, residence in nursing
homes prior to admission, use of nasogastric tubes or in-
dwelling urinary catheters or presence of pressure ulcers
and chronic wounds.
ASC were performed routinely on admission and dis-
charge from wards by swabbing nares, axilla and groin
and using direct culture on chromogenic media. Estimated
sensitivity of direct culture on chromogenic media is ap-
proximately 84% when compared to PCR detection, and
would also be dependent on sampling technique [21]. This
could have resulted in some false negative results from pa-
tients who were prevalent carriers but swab negative on
admission. Performing ASC weekly during admission or
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screening more sites (e.g. throat) may have provided more
accuracy but also increase costs and been difficult to im-
plement. Using time that MRSA colonisation was first
detected as a proxy for actual MRSA acquisition may mask
a time of undetected carriage however, we believe that for
the majority of patients this was of very short duration and
will not significantly affect the analysis. It is not routine
practice at our hospital to perform ASC on outpatients,
thus we could not follow patients to determine whether
the MRSA colonisation was persistent. In addition, we
could not control for other MRSA exposures after dis-
charge from hospital. These may be important in patients
with longer periods between detected MRSA colonisation
and subsequent infection. Molecular typing on paired iso-
lates representing colonisation and infection in the same
patient would be useful to confirm the link between colon-
isation and infection. The local MRSA epidemiology in
Singapore is virtually limited to two Multilocus Sequence
Types (ST239 and ST22) [22]. Typing methodologies
with greater discriminatory power such as Pulsed Field
Gel Electrophoresis or Whole Genome Sequencing would
therefore be required; however, only the first MRSA isolate
from each patient was routinely stored by our hospital la-
boratory so pairs were not available for typing.
Conclusion
In conclusion, our study shows that approximately 15% of
patients who acquired MRSA developed a subsequent
MRSA infection. Median time to infection was 22 days
and the risk of infection in those colonised was highest in
the peri-hospitalisation period. Patients developing MRSA
infection were at risk of infection-related re-admission
and had higher crude mortality rates than those patients
without MRSA infection. These results confirm that pre-
vention of MRSA acquisition in hospitals should be an im-
portant goal of programmes to reduce MRSA infections.
At the same time, targeting interventions such as decolon-
isation therapy and enhanced efforts to prevent device-
associated infection to reduce development of infection in
patients who newly acquire MRSA colonisation may also
have a key role. Since most infections occur soon after col-
onisation, useful further work would include the study of
immune mechanisms that may offer partial longer term
protection including potentially prophylactic or thera-
peutic vaccines.
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